October 7, 2011
Takeda Pharmaceutical has positioned its type 2 diabetes treatment Liovel (alogliptin + pioglitazone), launched in September, as a product of the Nesina DPP-4 (dipeptidyl peptidase-4) inhibitor family of drugs, and will provide information through its 2,000 MRs. Having determined that...read more